Allison DeAngelis

Allison DeAngelis is a biotech reporter at STAT, covering biopharma startups and venture capital. Prior to joining STAT, Allison covered the drug industry at Insider and the Boston Business Journal. She was named the Washington Newspaper Publishers Association's News Writer of the Year in 2016. She is based in Boston and, in non-pandemic times, enjoys traveling internationally.

Biography:  https://www.statnews.com/staff/allison-deangelis/

54%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

75%

Examples:

  • Amylyx's co-CEOs publicly promised that they would withdraw the drug if further testing failed to show a benefit. This promise was not kept.
  • The author states that Relyvrio has been proven to be effective when in fact its approval was contentious and based on limited evidence.

Conflicts of Interest

50%

Examples:

  • Amylyx's co-CEOs publicly promised that they would withdraw the drug if further testing failed to show a benefit. This promise was not kept.
  • The author states that Relyvrio has been proven to be effective when in fact its approval was contentious and based on limited evidence.

Contradictions

100%

Examples:

  • Amylyx's co-CEOs publicly promised that they would withdraw the drug if further testing failed to show a benefit. This promise was not kept.
  • The author states that Relyvrio has been proven to be effective when in fact its approval was contentious and based on limited evidence.

Deceptions

30%

Examples:

  • Amylyx's co-CEOs publicly promised that they would withdraw the drug if further testing failed to show a benefit. This promise was not kept.
  • The author states that Relyvrio has been proven to be effective when in fact its approval was contentious and based on limited evidence.

Recent Articles

ALS Therapy Relyvrio Fails in Confirmatory Trial, Amylyx Pharmaceuticals Pulls it Off the Market

ALS Therapy Relyvrio Fails in Confirmatory Trial, Amylyx Pharmaceuticals Pulls it Off the Market

Broke On: Thursday, 04 April 2024 Amylyx Pharmaceuticals has pulled Relyvrio, an ALS therapy, off the market after it failed in a confirmatory trial. The drug did not improve patients' physical function on the revised ALS functional rating scale compared to placebo.